National Institutes of Health Director Jay Bhattacharya faced more than 90 minutes of pointed questioning from senators on Thursday morning over the Trump administration’s proposed cuts to federal biomedical research funding and the organizational upheaval that has defined his first year running the agency. Both Republican and Democratic members of the Senate Appropriations Committee expressed concern that the administration’s budget proposals and grant terminations are threatening American leadership in medical science. The hearing underscored growing bipartisan unease with the scale and pace of changes at NIH.
Story Highlights
- Trump’s fiscal year 2027 budget proposes cutting NIH funding by $5 billion and eliminating five of the agency’s 27 institutes
- As of May 17, NIH had allocated only $10.09 billion of its $47 billion FY2026 budget — well below historical spending rates at this point in the fiscal year
- Only 12 of NIH’s 27 institutes currently have permanent directors; 15 are led by acting directors
What Happened
National Institutes of Health Director Jay Bhattacharya testified before the Senate Appropriations Committee Thursday morning on President Donald Trump‘s fiscal year 2027 budget request. The White House is seeking a $5 billion reduction in NIH funding next year, including cuts to grant and research programs the administration argues “broke the trust of the American people with wasteful spending, misleading information, risky research, and the promotion of dangerous ideologies that undermine public health.”
The Trump FY2027 budget, released in April, proposes cutting the agency’s budget by $5 billion and eliminating five of its 27 institutes. Those proposals are considered unlikely to be enacted in full, given lawmakers’ strong rebuke of Trump’s 2026 proposal, which had called for even steeper cuts. As of May 17, the NIH had allocated $10.09 billion of its $47 billion budget for fiscal year 2026 — significantly below the historical average of $14.75 billion spent at this same point in the fiscal year between 2021 and 2024.
Senator Patty Murray of Washington expressed concern about funding cuts for the National Institute of Allergy and Infectious Diseases and the agency losing staff, including top officials. “I know you’re scrambling to rehire, but it just seems like we have dismantled our infectious disease research and developmental pipeline, and we will pay the price,” she said. Bhattacharya responded that priorities had shifted toward allergy and immunology and that “some new leadership” was needed as a result.
The hearing was Bhattacharya’s first appearance before this particular Senate panel and amounted to a review of his first ten months as NIH director. Although some Republicans expressed support, for much of the nearly two-hour session Bhattacharya was forced to address bipartisan concerns about the impact of the Trump administration on public health and biomedical research. Senator Susan Collins of Maine expressed worry that deep cuts and grant terminations “could jeopardize” American leadership in medical research and drive young scientists to leave for Europe and China.
Senators also expressed concern that 15 of the agency’s 27 institutes are currently led by acting directors. Bhattacharya appeared alongside five of the 12 permanent institute directors remaining at the NIH.
Why It Matters
The NIH is the world’s largest funder of biomedical research, channeling tens of billions of dollars annually into university laboratories, hospitals, and research centers across the country. Its work underpins the development of treatments for cancer, Alzheimer’s disease, infectious illness, and chronic conditions that affect hundreds of millions of Americans. When its grant-making slows or stops, the effects cascade rapidly through academic medical centers, pharmaceutical pipelines, and early-career scientists whose careers depend on federal funding continuity.
The bipartisan character of Thursday’s criticism is the most politically significant aspect of the hearing. Republican senators including Collins and committee chair Shelley Moore Capito have consistently pushed back against the administration’s proposed cuts to NIH, recognizing that major research universities and hospitals in their states depend on the agency’s funding. That internal GOP resistance means the administration’s full budget proposals are unlikely to survive the appropriations process intact, but the existing grant terminations and spending slowdowns have already caused measurable disruption.
The budget hearing comes as questions swirl around hantavirus after several people died aboard a cruise ship after contracting the virus. Bhattacharya, who is also serving as acting director of the Centers for Disease Control and Prevention, has brushed off comparisons between the virus and COVID-19. The dual role places enormous institutional responsibility on a single official at a moment when both agencies are navigating funding pressures and public credibility challenges.
The workforce situation at NIH is a concrete indicator of institutional stress. A reduction from 21,000 staff to approximately 17,300 — including the departure of more than 1,100 people with doctoral degrees — represents a significant erosion of specialized institutional knowledge that cannot be quickly rebuilt even if funding is restored.
Economic and Global Context
Biomedical research is a major economic driver in the United States. The NIH estimates that each dollar of federal research funding generates several dollars in economic activity through employment, technology transfer, patent licensing, and the commercialization of treatments developed from basic science. A sustained reduction in grant-making therefore has downstream effects on the pharmaceutical and biotechnology sectors, which are key components of American economic and trade competitiveness.
The talent competition dimension is equally significant. Research universities in Europe and China have been actively recruiting American scientists who have lost federal funding or who perceive a deteriorating research environment in the United States. If that brain drain accelerates, it could affect U.S. competitiveness in biomedical innovation over a decade-long horizon — a concern that transcends any single budget cycle.
Investor confidence in the American biotech sector has shown signs of strain. Venture capital flows into early-stage life sciences companies depend partly on confidence that NIH-funded basic research will continue to generate the discoveries that form the basis of commercial drug development. Uncertainty about NIH’s funding trajectory introduces risk into investment models that had previously treated federal research support as a stable baseline.
From a global health security perspective, the effective hollowing out of NIAID — the institute responsible for infectious disease research — at a moment when a novel hantavirus cluster has triggered public concern raises uncomfortable questions about institutional readiness. Partners in the World Health Organization and allied nations watch U.S. public health infrastructure closely, and visible turbulence at the agency responsible for pandemic preparedness has measurable effects on confidence in multilateral health frameworks.
Implications
For researchers and universities, the immediate implications are concrete. Institutions with frozen or terminated grants face difficult decisions about whether to continue funding researchers on internal reserves — a financially unsustainable approach for most — or to let projects and personnel go. The longer the funding uncertainty persists, the harder it becomes to resume work even when grants are eventually restored.
For the Trump administration, Thursday’s hearing exposed the limits of its ability to reshape NIH through budget pressure alone. Congressional opposition, including from key Republicans, means the full scope of the proposed restructuring is unlikely to be legislated. But the administration has demonstrated it can achieve significant change through executive action — terminating grants, replacing leadership, and redirecting institutional priorities — without congressional approval.
For voters, the NIH debate is abstract in the short term but intensely personal in the long term. Americans diagnosed with cancer, Alzheimer’s, or rare diseases, and the families who support them, have a direct stake in the survival of a research enterprise that produces the treatments and cures they may depend on in the future. As that connection becomes clearer in public discourse, the political calculus of deep research cuts could shift meaningfully.
For Bhattacharya personally, Thursday’s testimony was a difficult public accountability moment. He entered the hearing defending a budget that even his Republican allies on the committee could not support in full, while simultaneously explaining an unprecedented slowdown in grant spending that has disrupted research nationwide. His ability to maintain credibility with both the White House and the scientific community will determine how effectively he can manage the agency through the remainder of Trump’s term.
